Treatment Practices, Outcomes, and Costs of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis, United States, 2005–2007

Emerging Infectious Diseases (Impact Factor: 6.75). 05/2014; 20(5):812-21. DOI: 10.3201/eid2005.131037
Source: PubMed


To describe factors associated with multidrug-resistant (MDR), including extensively-drug-resistant (XDR), tuberculosis (TB) in the United States, we abstracted inpatient, laboratory, and public health clinic records of a sample of MDR TB patients reported to the Centers for Disease Control and Prevention from California, New York City, and Texas during 2005-2007. At initial diagnosis, MDR TB was detected in 94% of 130 MDR TB patients and XDR TB in 80% of 5 XDR TB patients. Mutually exclusive resistance was 4% XDR, 17% pre-XDR, 24% total first-line resistance, 43% isoniazid/rifampin/rifabutin-plus-other resistance, and 13% isoniazid/rifampin/rifabutin-only resistance. Nearly three-quarters of patients were hospitalized, 78% completed treatment, and 9% died during treatment. Direct costs, mostly covered by the public sector, averaged $134,000 per MDR TB and $430,000 per XDR TB patient; in comparison, estimated cost per non-MDR TB patient is $17,000. Drug resistance was extensive, care was complex, treatment completion rates were high, and treatment was expensive.

Download full-text


Available from: Edward A Graviss, Jun 19, 2014
  • Source
    • "For the US, Rajbhandary et al. analyzed the inpatient costs of 13 MDR-TB patients enrolled in a CDC study in 1995/1996 and estimated the remaining costs from a societal perspective [28]. Marks et al. [29], in their impressive population-based sample of 134 patients that comprised 36% (130/364) of all MDR-TB and 56% (5/9) of all XDR-TB cases reported in the United States during 2005e2007, calculated direct-plus-productivity-loss costs of USD 260,000 per MDR-TB patients and USD 554,000 per Table 5 GKV costs of diagnosing MDR-TB and monitoring MDR-TB treatment (in V). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: 4220 new cases of tuberculosis (TB) were reported in Germany in 2012; of those, 65 cases were multidrug-resistant TB (MDR-TB) or extensively multidrug-resistant TB (XDR-TB) cases. However, there is only limited information on the economic consequences of drug resistance patterns on the treatment costs of MDR-and XDR-TB patients. Methods: On the basis of drug susceptibility of the single MDR-TB/XDR-TB strains the direct medical costs of suitable therapies were calculated according to the current guidelines of the World Health Organization (WHO) and those of the German Central Committee against Tuberculosis. These costs were combined with hospital and outpatients monitoring costs and followed the most recent German invoicing system and health statistics. Total drug and monitoring costs and were determined by Monte-Carlo simulation comprising all different options. Results: According to this, the mean drug costs were €51,113.22 (range €19,586.14 to €94,767.90). The weighted costs for hospitalization were €26,000.76 per patient compared to only €2,192.13 for primary outpatients; the total treatment costs of MDR-TB amounted to €64,429.23. These are joined by the costs due to loss of productivity, varying between €17,721.60 and €44,304. From a societal perspective, the total cost per MDR-TB/XDR-TB case reach an amount between €82,150 and €108,733 per case, respectively. Conclusion: Cost analyses based on strain resistance patterns allow more reliable estimates of the real costs of treating MDR-TB/XDR-TB than do methods that ignore this factor. Advantageously, they demonstrate the economic impact of drug-resistant TB in low-incidence countries. Costs of productivity loss is of new importance because of the length of MDR-XDR therapy, but its true share of total costs has still to be determined.
    Full-text · Article · Nov 2014 · Respiratory Medicine
  • Source
    • "Extensive resistance: it defines the ability of organisms to withstand the inhibitory effects of at least one or two most effective antimicrobial drugs. Also termed as XDR, this seemed to arise in patients after they have undergone a treatment with first line drugs, for example, XDR-TB resistance against fluoroquinolone [35, 36]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The resistance among various microbial species (infectious agents) to different antimicrobial drugs has emerged as a cause of public health threat all over the world at a terrifying rate. Due to the pacing advent of new resistance mechanisms and decrease in efficiency of treating common infectious diseases, it results in failure of microbial response to standard treatment, leading to prolonged illness, higher expenditures for health care, and an immense risk of death. Almost all the capable infecting agents (e.g., bacteria, fungi, virus, and parasite) have employed high levels of multidrug resistance (MDR) with enhanced morbidity and mortality; thus, they are referred to as "super bugs." Although the development of MDR is a natural phenomenon, the inappropriate use of antimicrobial drugs, inadequate sanitary conditions, inappropriate food-handling, and poor infection prevention and control practices contribute to emergence of and encourage the further spread of MDR. Considering the significance of MDR, this paper, emphasizes the problems associated with MDR and the need to understand its significance and mechanisms to combat microbial infections.
    Full-text · Article · Jul 2014 · Interdisciplinary Perspectives on Infectious Diseases
    • "Following CMS guidelines, only measures that are based on a sample of at least 25 patients for a given condition are included in the many healthcare scholars (e.g.,Every et al. 1996, Chen et al. 2010, Marks et al. 2014) and state agencies (e.g., Ohio Bureau of Workers Compensation, Wisconsin ForwardHealth); that is, we convert each hospital's total inpatient operating charges for their fiscal years beginning in time periods t to t + 5 to 2012 U.S. dollars using the consumer price index for inpatient hospital services. We then divide these inflation-adjusted inpatient charges by the total number of inpatient discharges and exclude the top and bottom 1% to prevent outliers from unduly affecting the results (Every et al. 1996). "

    No preview · Article ·
Show more